Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

by Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken
Published 2016-10-01